CLAIMS

1. A compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime.

2. The compound according to claim 1, wherein the purity of the compound is at least in the range of 85% to 99.9%.

3. The compound according to claim 2, wherein said compound is formulated for administration to a subject in need thereof in a single dose of from 50 mg to 900 mg of said compound.

4. The compound according to claim 3, wherein said single dose comprises from 100 mg to 600 mg of said compound.

5. The compound according to claim 2, wherein said compound is formulated for administration concomitantly or separately with at least one compound selected from the group consisting of calcium channel blockers, magnesium sulfate, selective prostaglandin modulators, beta-2-adrenergic agonists, beta-3-adrenergic receptor agonists, and corticosteroids.

6. The compound according to claim 2, wherein said compound is stable in plasma.

7. The compound according to claim 3, wherein the subject in need thereof is a mammal.

8. The compound according to claim 7, wherein the mammal is a human.

9. A compound according to claim 2 for use as a medicament.

10. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier, diluent, or excipient.

11. The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition is formulated for oral, vaginal, or intravenous administration.

12. A process for preparing and isolating the compound according to claim 2 comprising the steps of: a) Loading a crude isomeric mixture comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime on a Silica gel chromatography column;

b) Purifying with 1% alcohol in organic solvent; and
c) Purifying with 2% alcohol in organic solvent.

13. The process according to claim 15, wherein said alcohol is methanol and said organic solvent is toluene.